Simpson Thacher Represents Daiichi Sankyo in its Proposed Acquisition of Plexxikon Inc.
03.01.11
This is only gets display when printing
The Firm is representing Daiichi Sankyo in connection with its proposed acquisition of Plexxikon Inc. for an initial purchase price of $805 million. Additional potential payments totaling approximately $130 million will be made upon the achievement of certain milestones associated with the approval of PLX 4032, a late-stage oncology product.
Plexxikon Inc., a pharmaceutical company based in Berkeley, California, is a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease. Daiichi Sankyo is a Japan-based global pharmaceutical company.
The Simpson Thacher team for this transaction included Gary Horowitz, Ellen Rosenberg, Maura Whelan and Scott Naturman (M&A); Noah Leibowitz and Alexander Key (Intellectual Property); Steve Todrys and Jason Vollbracht (Tax); Tristan Brown (Executive Compensation and Employee Benefits); and Ken Ehrhard (Antitrust).